PROLOR BIOTECH
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.
PROLOR BIOTECH
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2001-01-01
Address:
Nes Ziyona, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.prolor-biotech.com
Total Employee:
51+
Status:
Closed
Contact:
866 644 7811
Email Addresses:
[email protected]
Total Funding:
58.68 M USD
Technology used in webpage:
Amazon
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Medarex
Medarex, Inc. discovers, develops, and commercializes human antibody-based therapeutic products.
Onegene Biotechnology
Onegene Biotechnology develops highly potent tri- or intraspecific protein-based drugs.
Founder
Investors List
Cybele Holdings
Cybele Holdings investment in Venture Round - PROLOR Biotech
SternAegis
SternAegis investment in Venture Round - PROLOR Biotech
Official Site Inspections
http://www.prolor-biotech.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "PROLOR Biotech"
PROLOR Biotech - Crunchbase Company Profile
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy …See details»
Prolor Biotech Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Prolor Biotech Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Endocrinology and Metabolic Disease, Nervous System Diseases, …See details»
Prolor Biotech - Company Profile - Tracxn
Dec 10, 2024 Prolor Biotech - Developing protein therapeutics for hemophilia and other diseases. Acquired by Opko Health. Raised funding over 3 rounds from 2 investors. Founded …See details»
Prolor Biotech, Inc. – Montrose Capital Partners
Dec 4, 2024 PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology, primarily to develop longer-acting proprietary versions of already approved …See details»
OPKO Health - Company Profile Page | Startup Nation Finder
Oct 19, 2023 OPKO Biologics, previously known as Prolor Biotech, is a clinical-stage company that concentrates on creating long-acting versions of therapeutic proteins and peptide drugs. …See details»
OPKO Biologics - Craft
OPKO Biologics (formerly Prolor Biotech) is a company developing bio-better long-acting versions of therapeutic proteins and peptide drugs, utilizing CTP and reversible PEGylation …See details»
Opko Biologics - Products, Competitors, Financials, Employees ...
Opko Biologics, formerly Prolor Biotech, is a clinical stage biopharmaceutical company applying unique technologies, including CTP technology, primarily to develop longer-acting versions of …See details»
Prolor Biotech Ltd.:Company Profile & Technical …
Prolor Biotech is headquartered in Israel HaMerkaz. Prolor Biotech was founded in 2001. Related Topics. Therapeutic protein Medical equipment Pharmacy and Therapeutics. Login to view all …See details»
OPKO Health acquires Israel’s PROLOR Biotech for $480m
Apr 25, 2013 PROLOR Biotech and OPKO Health researchers are working on new drug-products for hemophilia, obesity and diabetes. (Shutterstock.com) By Viva Sarah Press. April 25, 2013, Updated July 20, 2015 Print; ... A non-profit …See details»
OPKO Health to acquire Prolor Biotech for $480M
Apr 24, 2013 OPKO Health announced today that it is poised to acquire Israel-based Prolor Biotech in an all-stock transaction valued at $480 million, or $7 per share of Prolor common …See details»
PROLOR Biotech, Inc. - Robbins LLP
Robbins LLP is investigating the acquisition of PROLOR Biotech, Inc. (NYSE MKT: PBTH) by OPKO Health, Inc. (NYSE: OPK). On April 24, 2013, PROLOR and OPKO announced the …See details»
Prolor Biotech - cosmeticsbusiness.com
Through digital, live and print products, Cosmetics Business informs and inspires business leaders and decision-makers around the world. With a digital-first strategy, the Group’s Editors …See details»
PROLOR Biotech - Foreign Startup | Startup Nation Finder
Apr 16, 2014 PROLOR Biotech, develops proprietary versions of therapeutic proteins and peptide drugs already approved for medical therapy, such as human growth hormone. The …See details»
Gornitzky advises Prolor Biotech in their merger with Opko Health ...
Apr 24, 2013 Gornitzky advised Prolor Biotech Inc. (AMEX: PBTH; TASE: PBTH) in connection with their proposed merger with Opko Health Inc. (NYSE: OPK). Under the merger agreement, …See details»
PROLOR BIOTECH INC innovation strategy - GoodIP
PROLOR BIOTECH INC has a total of 21 patent applications. Its first patent ever was published in 2010. It filed its patents most often in China, WIPO (World Intellectual Property Organization) …See details»
Prolor Biotech Ltd. (Prolor Biotech Ltd.) - 药物管线_专利_临床试验_ …
了解Prolor Biotech Ltd. (Prolor Biotech Ltd.)公司的药物管线，治疗领域，技术平台，以及它的1项临床试, 1篇新闻，疾病领域:内分泌与代谢疾病，神经系统疾病，技术平台:小分子化药，合成 …See details»
PROLOR Biotech's Longer-Acting Human Growth Hormone
Oct 5, 2010 PROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, …See details»
Atherosclerosis (PROLOR Biotech) - Drug Targets, Indications, …
Atherosclerosis (PROLOR Biotech), Initially developed by Prolor Biotech Ltd., Now, its global highest R&D status is Discontinued, Therapeutic Areas: Cardiovascular Diseases. ...See details»
Prolor Biotech - Facebook
Prolor Biotech. 106 likes. Biotechnology CompanySee details»